Relay Therapeutics, Inc. $RLAY Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) by 32.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 278,327 shares of the company’s stock after purchasing an additional 67,859 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Relay Therapeutics were worth $5,207,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Alphabet Inc. acquired a new stake in shares of Relay Therapeutics during the 2nd quarter worth $26,382,000. California State Teachers Retirement System raised its holdings in shares of Relay Therapeutics by 47.9% in the 1st quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock worth $1,732,000 after purchasing an additional 56,422 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at about $1,323,000. Sanctuary Advisors LLC acquired a new stake in Relay Therapeutics during the 2nd quarter worth approximately $1,995,000. Finally, Bank of America Corp DE raised its holdings in Relay Therapeutics by 86.1% in the first quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock valued at $19,280,000 after buying an additional 896,746 shares during the period. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Activity at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 187,163 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the completion of the sale, the chief financial officer owned 177,461 shares of the company’s stock, valued at approximately $3,011,513.17. The trade was a 51.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $19.40, for a total transaction of $116,400,000.00. Following the completion of the sale, the insider directly owned 21,904,963 shares of the company’s stock, valued at $424,956,282.20. The trade was a 21.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,414,147 shares of company stock worth $123,723,695 over the last 90 days. Company insiders own 5.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RLAY shares. Barclays raised their target price on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Raymond James Financial reiterated a “strong-buy” rating on shares of Relay Therapeutics in a research note on Tuesday, May 19th. JPMorgan Chase & Co. boosted their price target on Relay Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. HC Wainwright boosted their target price on shares of Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Zacks Research raised shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Relay Therapeutics Trading Up 0.4%

Relay Therapeutics stock opened at $19.11 on Wednesday. Relay Therapeutics, Inc. has a 52 week low of $3.87 and a 52 week high of $21.27. The stock has a market cap of $4.19 billion, a P/E ratio of -12.17 and a beta of 1.69. The stock has a 50 day moving average of $19.35 and a 200-day moving average of $15.27.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The company had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. As a group, equities analysts predict that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.